Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: August 7, 2020
Expires: August 7, 2021
45 minutes to complete

Accredited By

Target Audience

This activity is intended for PCPs and other community-based practitioners who may encounter at-risk patients who should be assessed for IPF and/or referred to specialty ILD care center.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Outline risk factors associated with IPF
  • Interpret findings from the steps in a differential diagnosis of IPF
  • Describe comprehensive care plans for patients with IPF
  • Discuss the role of primary care providers in the diagnosis and management of IPF

Activity Description

In this activity, pulmonologist Gregory Cosgrove, MD, discusses the signs and symptoms of IPF to help PCP learners identify at-risk patients and achieve goals of earlier referral and treatment initiation, ultimately improving patient quality of life. The activity also features an animated whiteboard to illustrate take-home points for the PCP audience.

Statement of Educational Need

Clinicians require education surrounding appropriate identification of IPF patients, implications of guidelines to practice, and the value of referral to a specialist. This activity is designed to provide practical guidance from an expert faculty to help increase awareness of signs and symptoms of IPF, and current and emerging treatment options, in order to optimize patient care across a multidisciplinary team.


Gregory P. Cosgrove, MD, FCCP
Associate Professor
National Jewish Health & University of Colorado-Denver
Chief Medical Officer
Pulmonary Fibrosis Foundation
Denver, CO

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:
Grants/Research Support Recipient: Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Global Blood Therapeutics
Advisor or Review Panel Member: Boehringer Ingelheim, Genentech, Global Blood Therapeutics
Consultant: Boehringer Ingelheim, Genentech, Global Blood Therapeutics 

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None 

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Genentech, a member of the Roche Group.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.